Mark Wildgust: Outstanding Results from the FLAIR Study Presented at EHA25
Mark Wildgust, Vice President, Global Medical Affairs, Oncology at The Janssen Pharmaceutical Companies of Johnson and Johnson, shared a post on X:
“Outstanding results from the FLAIR study presented at EHA25 today and published in the NEJM.”
Title: Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia
Journal: NEJM
Authors: Talha Munir, Sean Girvan, David A. Cairns, Adrian Bloor, David Allsup, Abraham M. Varghese, Satyen Gohil, Shankara Paneesha, Andrew Pettitt, Toby Eyre, Christopher P. Fox, Francesco Forconi, Constantine Balotis, Nicholas Pemberton, Oonagh Sheehy, John Gribben, Nagah Elmusharaf, Simona Gatto, Gavin Preston, Anna Schuh, Renata Walewska, Lelia Duley, Nichola Webster, Surita Dalal, Andrew Rawstron, Dena Howard, Anna Hockaday, Sharon Jackson, Natasha Greatorex, Sue Bell, David Stones, Julia M. Brown, Piers E.M. Patten, Peter Hillmen
Take a moment to look 25 Posts Not to Miss from EHA 2025
-
Nov 10, 2025, 10:16Pablo Corral on Enlicitide: The Phase 3 CORALreef HeFH Trial Brings a Major Step Forward
-
Nov 10, 2025, 10:15Laurent Bertoletti Invites You to the Joint INNOVTE and GITA Meeting on Hormones and Thrombosis
-
Nov 10, 2025, 10:15Christopher Cannon: DOAC Monotherapy Wins Again
-
Nov 10, 2025, 10:14Marieke Kruip on Sex differences in Outcomes of VKA Treatment in Patients with Mechanical Heart Valve
-
Nov 10, 2025, 10:14Ana Paula Lacombe: From Research to Bedside, Innovation in Stroke Care is Moving Fast!
-
Nov 10, 2025, 10:13Jan Sloves: Understanding Iliofemoral DVT – What You Can’t Afford to Miss
-
Nov 10, 2025, 10:12Mohamed Rawy Shares a Comprehensive Guide For Anticoagulation
-
Nov 10, 2025, 10:10Marc Carrier: Proud to Share the Results of the WAVe Study
-
Nov 10, 2025, 10:07Frederik Denorme – The New PI at the Laboratory of Cell Biology and Histology at University of Antwerp